Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.

CONCLUSION: This study demonstrates an efficient and promising means for assessing circulating autoantibody titers that could be useful in selecting advanced NSCLC patients for PD-1/-L1 directed immunotherapy. Further exploration and validation of this paradigm is warranted to advance current treatment selection methods for this therapeutic strategy. PMID: 33434603 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33434603?dopt=Abstract

Source: Journal of Immunological Methods - January 9, 2021 Category: Allergy & Immunology Authors: Tarhoni I, Wakefield CJ, Kollipara R, Fidler MJ, Batus M, Bonomi P, Borgia JA Tags: J Immunol Methods Source Type: research